[SEQ CHAPTER \h \r 1]**Primary Reviewer:** Cassandra Kirk, Ph.D., Biologist, Emerging Technologies Branch **Date:** 4/8/20

[SEQ CHAPTER \h \r 1]

[SEQ CHAPTER \h \r 1]Secondary Reviewer: Chris A. Wozniak, Ph.D., Biotechnology Special Assistant, OPP/BPPD **Date:**

DATA EVALUATION RECORD

[SEQ CHAPTER \h \r 1]**REQUIREMENT:** EPA OCSPP

TEST MATERIAL (PURITY): *Aedes aegypti* OX5034

SYNONYMS: OX5034

CITATION: Proposed Arbovirus qRT-PCR Testing Protocol Outline, Volume 3, EUP Submission; MRID 51094403; March 32, 2020

SPONSOR: Oxitec Ltd, 71, Milton Park, Abingdon, Oxfordshire, OX14 4RX United Kingdom

AUTHOR: Oxitec Ltd.

TEST SITE: Milton Park, Abingdon, Oxfordshire, UK.

COMPLIANCE: Good Laboratory Practice Standards, 40 CFR Part 160, are not applicable to this report. However, the study was conducted according to accepted scientific methods and the raw data and study records have been retained.

This DER does not contain FIFRA CBI.

EXECUTIVE SUMMARY:

The developer of the male-selective *Aedes aegypti* OX5034 mosquito, Oxitec Ltd., used commercially available test kits (VecTOR Test Systems Inc.) to demonstrate the absence of arbovirus infections in the OX5034 production colony. OX5034 mosquitoes were tested for the detection of arboviruses including Dengue, Chikungunya, West Nile Virus (WNV), Saint Louis encephalitis (SLE), eastern equine encephalitis (EEE), Western Equine Encephalitis (WEE), Venezuelan Equine Encephalitis (VEE), Mayaro (MAY) and Sindbis (SIN) viruses. The Agency disagreed with the study author's conclusion that the results of the Vector Test® Systems Inc. arbovirus detection kits used for detection of Chikungunya, Dengue, WNV, SLE, EEE, WEE, VEE, MAY and SIN viruses confirms that the OX5034 production colony is free of arbovirus infection, due to uncertainties regarding the sensitivity and specificity of the assays utilized for

arbovirus testing and due to the lack of testing for Zika virus. As a result of this review, EPA requested new arbovirus testing parameters for screening the OX5034 colony for arbovirus infection based on review of MRID 50889425 in a 75-day deficiency letter (19 March 2020). In response to the Agency's request, Oxitec submitted a rationale detailing which arboviruses they have determined are relevant for screening the OX5034 colony which, included a subset of the arboviruses previously tested for using the VectorTEST® kits. Oxitec purported that not all of the viruses detectable by each kit are vectored by *Aedes aegypti.* The overall rationale stated "Oxitec proposes conducting qRT-PCR-based arbovirus testing only for viruses that are known to be transmitted by *Aedes aegypti* in the geographic range relevant for releases, *i.e.* FL and TX. These viruses include Dengue and Chikungunya Viruses, but not the Equine Encephalitis Viruses (SLE, EEE, WEE, VEE), West Nile Virus, Mayaro Virus or Sindbis Virus." Oxitec also presented a list of commercial kits available for detection of arboviruses in serum and/or mosquito samples.

The Agency agrees that arbovirus testing is only relevant for those viruses for which *Aedes aegypti* is a major vector (*i.e.* Yellow Fever Virus, Dengue Viruses, Chikungunya Virus, and Zika Virus), however the Agency disagrees that testing requirements should be based on the viruses that are known to be transmitted by *Aedes aegypti* in the geographic range relevant for releases, *i.e.* FL and TX. Risk for arbovirus infection of the source colony would occur in the UK where the colony is maintained, not the release site. For the EUP the colony will be maintained at Oxitec's insectary in Milton Park, UK and OX5034 male eggs will be shipped to the US release sites. The risk for colony infection is based on the presence of *Aedes aegypti* and the occurrence of the arboviruses the mosquito is capable of vectoring in the UK. The Agency conducted a review of the peer reviewed literature and public health databases and determined that there are no established populations of *Aedes aegypti* in the UK and that there have been no locally acquired cases of arboviral infections for which *Aedes aegypti* is a major vector. The Agency therefore concludes that because neither *Aedes aegypti* nor the arboviruses for which it is a vector are present in the UK, the risk of infection of arbovirus infection of the source colony is low. Therefore, arbovirus testing for the EUP is not required.

This submission is considered **SUPPLEMENTAL** for use in the risk assessment because the rationale regarding choosing which arboviruses to test for based upon the presence of the vector and viruses at the release sites is inappropriate for addressing risk of arboviral infection of the source colony located in the UK for the EUP.

PURPOSE:

In a 75-day deficiency letter (19 March 2020), EPA requested new arbovirus testing parameters for screening the OX5034 colony for arbovirus infection based on review of MRID 50889425. The letter requested the following:

"Oxitec must submit arbovirus testing data utilizing an RT-PCR method with demonstrated diagnostic validation, quantitative measures of analytical specificity and sensitivity, in addition to appropriate controls and sample size that effectively demonstrate that laboratory colonies are arbovirus (*i.e.* Dengue Virus, Chikungunya Virus, West Nile virus, Saint Louis Encephalitis, Eastern Equine Encephalitis, Western Equine Encephalitis, Venezuelan Equine Encephalitis,

Mayaro and Sindbis Viruses) free. A rationale must be provided for detection threshold as well as sample sizes tested. EPA requires testing methods describing the parameters above be submitted now and will require submission of confirmatory data that EPA must review and determine to be acceptable prior to any field release of mosquitoes."

The purpose of this data evaluation record is to review the submission provided by Oxitec in response to the Agency's request.

CLASSIFICATION: SUPPLEMENTAL

RESULTS:

In response to the Agency's request, Oxitec submitted a rationale detailing which arboviruses they have determined are relevant for screening the OX5034 colony which, included a subset of the arboviruses previously tested for using the VectorTEST® kits. The tests carried out and reported in MRID 50889425 used three kits available from VectorTEST® Inc. Oxitec purported that not all of the viruses detectable by each kit are vectored by *Aedes aegypti*. The ability of the kits to detect multiple viruses is a result of the similarity of the viral antigen protein detected (*e.g.* Chikungunya, transmitted by *Aedes aegypti*, has similar genetic sequence to other alphaviruses like EEE Virus, which is not transmitted by *Aedes aegypti*). The overall rationale stated "Oxitec proposes conducting qRT-PCR-based arbovirus testing only for viruses that are known to be transmitted by *Aedes aegypti* in the geographic range relevant for releases, *i.e.* FL and TX. These viruses include dengue and Chikungunya Viruses, but not the Equine Encephalitis Viruses (SLE, EEE, WEE, VEE), West Nile Virus, Mayaro Virus or Sindbis Virus." Oxitec also presented a list of commercial kits available for detection of arboviruses in serum and/or mosquito samples. These include, but are not limited to, those in presented in **Table 1.**

Table 1. Commercial and published kits/assays for arbovirus detection.

Supplier	Assay	Controls Supplied	Analyte Validated (Serum/Mosquito)	References
ThermoFisher	TaqMan Zika Virus Triplex Vector Screening Kit (ZIKV/DENV/CHIKV)	No	Mosquito	Lura and Brown, 2019
BioRad	Zika, Dengue, and Chikungunya (ZDC) Real-Time PCR Assays	Yes (Dengue, Zika and Chikungunya RNA sequences)	Mosquitoes and serum	https://www.biorad.com/webroot/web/pdf/lsr/literature/10000071135_digital_lock.pdf
Altona Diagnostics	RealStar® Zika Virus RT-PCR Kit 1.0 (WHO validated) RealStar® Dengue Virus RT-PCR Kit 2.0 RealStar® Chikungunya Virus RT-PCR Kit 2.0	Yes (Dengue, Zika and Chikungunya RNA sequences)	Serum	L'Huillier et al., 2017; Mat Jusoh and Shueb, 2017; Heitmann et al., 2018
CDC	Trioplex Real-time RT-PCR Assay	Inactivated virus samples for		[HYPERLINK "https://www.cdc.gov/zika/pdfs/trioplex-

		each virus (CDC; catalogue #KT0167)		real-time-rt-pcr-assay-instructions-for-use.pdf"]

Study Author's Conclusion:
Oxitec proposes the use of commercially available multiplex qRT-PCR testing kits for detection of Dengue (Serotypes 1-4), Chikungunya and Zika viruses, based on the relevance of *Aedes aegypti* for the transmission of these viruses. Oxitec proposes a sample size of 900 mosquitoes, analyzed as pooled samples of 10 mosquitoes, equating to a detection threshold of 0.3% infection in the Oxitec OX5034 mosquito colony. Assay specificity and sensitivity would not be re-determined as the assays cited are commercially available validated assays. Viral RNA sequences would be used as controls. The study author concludes that taken together, these assays would be sufficient to confirm that the OX5034 colony is free of arbovirus infection.

Reviewer's Comments:
***Aedes aegypti* vector competency**
Arthropod-borne viruses (arboviruses) are important causes of human disease nearly worldwide (Weaver and Reisen, 2010). The test kits previously purchased by Oxitec from VectorTEST® Inc were designed to detect a suite of arboviruses of medical importance in the US (*i.e.* the most prevalent arboviruses in the US that are of human health concern). These assays can simultaneously detect arboviruses transmitted by *Aedes aegypti* in addition to other vectors. The Agency agrees with Oxitec that arboviruses vectored by mosquito species other than *Aedes aegypti* are not relevant for screening because research and data indicate that *Aedes aegypti* are only competent at transmitting a limited number of arboviruses. The four viruses that have had the greatest impact on human health for which *Aedes aegypti* is the primary vector include the Yellow Fever Virus, Dengue Viruses, Chikungunya Virus, and Zika Virus (Souza-Neto et al., 2019). A few studies have demonstrated that *Aedes aegypti* can be infected with other arboviruses in addition to these four viruses, however, transmission of the virus to other hosts (*e.g.* humans, wildlife) once the mosquito is infected was found to be unlikely. For example, laboratory studies to examine the impact of *Wolbachia* on the replication of West Nile Virus in *Aedes aegypti* demonstrated that *Aedes aegypti* can be experimentally infected, however, no infectious virus was detected in saliva from these mosquitoes (Joubert and O'Neill, 2017). Major vectors for West Nile Virus include many *Culex spp.*; some of the most important include *Culex pipiens, tarsalis, modestus,* and *quinquefasciatus* (Chapman et al., 2018), not *Aedes aegypti.*

Formatted: Font: Italic

Serra et al. (2016), found non-engorged *Aedes aegypti* naturally infected with Mayaro Virus in the city of Cuiaba, a central region of Brazil, however either no or poor infection and dissemination rates were demonstrated when orally challenged with artificial blood meals containing Mayaro Virus at titers similar to those usually found in infected humans (Brustolin et al., 2018; Long et al., 2011), which may limit chances to initiate an urban transmission cycle. However, *Aedes aegypti* were able to experimentally transmit Mayaro Virus when taking a blood meal with high viral load; therefore, the authors concluded that the hypothesis that *Aedes aegypti* could contribute to urban transmission should not be completely neglected (Long et al., 2011). In addition, *Aedes aegypti* from Florida State (Wiggins et al., 2018) and from Iquitos (Peru) (Long et al., 2011) were competent to transmit Mayaro Virus in laboratory conditions. Major vectors of Mayaro Virus include *Haemagogus sp*. No wild transmission of Mayaro Virus by *Aedes aegypti* has been found to date (Pezzi et al., 2020).

A laboratory study conducted by Muturi et al. (2011) used *Aedes aegypti* as a model species to examine the effect of larval stress on vector competence for Sindbis Virus found that stress

during larval development may cause alterations in adult mosquito phenotype and immunity that can increase their susceptibility to pathogens. This study demonstrates that *Aedes aegypti* can be experimentally infected with Sindbis Virus in the laboratory, however it is not a major vector of the virus. Major vectors for Sindbis Virus include *Culex spp.* and *Culiseta spp.* (Chapman et al., 2018).

***Aedes aegypti* geographic range and surveillance in the UK**

The reviewer disagrees that testing for viruses that are known to be transmitted by *Aedes aegypti* in the geographic range relevant for releases, *i.e.* FL and TX is appropriate because the risk for arbovirus infection of the source colony would occur in the UK where the colony is maintained, not the release site. For the EUP the colony will be maintained at Oxitec's insectary in Milton Park, UK and OX5034 male eggs will be shipped to the US release sites. The risk for colony infection is based on the presence of *Aedes aegypti* and the occurrence of the arboviruses the mosquito is capable of vectoring in the UK.

The mosquito *Aedes aegypti* is found in tropical and sub-tropical regions where it is the major vector of Dengue Virus, Yellow Fever Virus, Chikungunya Virus and more recently, Zika Virus. Given the importance of *Aedes aegypti* as a vector of arboviruses and its propensity to be transported to new regions, the European Centre for Disease Prevention and Control (ECDC) has placed *Aedes. aegypti* on a list of potentially invasive mosquito species. Public Health England (PHE) runs the nationwide mosquito surveillance project which, conducts surveys for invasive mosquitoes in the UK. The UK currently has no known established populations of invasive *Aedes* mosquitoes (Medlock et al., 2019). *Aedes aegypti* was previously reported in the United Kingdom (UK) in 1865 and 1919 but did not establish on either occasion. More recently, it has reappeared in European countries and has been recorded in the Netherlands (not established) and Madeira (Portugal), as well as southern Russia, Georgia and Turkey (Dallimore et al., 2017). In 2014, a single male *Aedes aegypti* was found in Merseyside, England, however follow-up surveys determined that there was no established population (Dallimore et al., 2017).

Absence of arboviruses vectored by *Aedes aegypti* in the UK

None of the arboviruses (Dengue Virus, Chikungunya Virus, Yellow Fever Virus and Zika Virus) for which *Aedes aegypti* is a major vector occur naturally in the UK; it is a travel-associated infection. The most recent data in the European Centre for Disease Prevention and Control's (ECDPC) Surveillance Atlas for Infectious Disease show no locally acquired cases of these viruses (ECDPC, 2017). In recent years a small number of travel-related Chikungunya cases have been reported in England, Wales and Northern Ireland (EWNI) annually. Most have been acquired in the Indian sub-continent and South East Asia. In 2014, 295 cases of Chikungunya were reported in EWNI of which 88% had acquired their infection in the Caribbean and South America (Public Health England, 2014). Cases of Dengue in UK travelers are increasing, with most reported in travelers who visited Asia, the Americas and the Caribbean (Public Health England, 2014). In 2017, there were 465 cases of imported Dengue (ECDPC, 2017). No vector-borne locally acquired Zika Virus disease cases were reported by EU/EEA countries in Europe as of week 12, 2019 (ECDPC, 2019). According to a risk assessment for Zika Virus released in April, 2019 by the ECDPC, between 2015 and week 12 of 2019, 22 EU/EEA Member States reported 2 398 travel-associated Zika Virus infections through the European Surveillance System. France reported 48% of the cases, Spain 15% and the UK, 9%. In

2017, the ECDPC reported one travel-related case of Yellow Fever in the Netherlands; there were no confirmed cases of Yellow Fever in the UK (ECDPC, 2017).

Reviewer's Recommendations:
The Agency concludes that because neither *Aedes aegypti* nor the arboviruses for which it is a vector are present in the UK, the risk of infection of arbovirus infection of the source colony is low. Therefore, arbovirus testing for the EUP is not required. It should be noted that because testing is not required for the EUP, the test kits cited in **Table 1**. were not reviewed in detail and therefore a determination regarding the adequacy of the proposed testing protocol outline has not been made at this time.

CONCLUSION: SUPPLEMENTAL

REFERENCES:

Brustolin, M., Pujhari, S., Henderson, C.A., et al., 2018. Anopheles mosquitoes may drive invasion and transmission of Mayaro virus across geographically diverse regions. PLoS Neglected Trop. Dis. 12, e0006895.

Chapman GE, Baylis M, Archer D, Daly JM. 2018. The challenges posed by equine arboviruses. Equine Veterinary Journal 50:436–445. DOI: 10.1111/evj.12829.

Dallimore T, Hunter T, Medlock JM, Vaux AGC, Harbach RE, Strode C. 2017. Discovery of a single male Aedes aegypti (L.) in Merseyside, England. Parasit Vectors. 2017 Jun 24;10(1):309. doi: 10.1186/s13071-017-2251-0.

European Centre for Disease Prevention and Control. 2019. Zika virus transmission worldwide, Rapid Risk Assessment 9 April, 2019: [HYPERLINK "https://www.ecdc.europa.eu/sites/default/files/documents/zika-risk-assessment-9-april-2019.pdf"]

European Centre for Disease Prevention and Control. 2017. Surveillance Atlas for Infectious Disease; Accessed April 8, 2010: [HYPERLINK "http://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=16"]

Health and Safety Executive. 2020. West Nile Virus; [HYPERLINK "https://www.hse.gov.uk/agriculture/zoonoses-data-sheets/west-nile-virus.pdf"]

Joubert DA, O'Neill SL. 2017. Comparison of Stable and Transient Wolbachia Infection Models in Aedes aegypti to Block Dengue and West Nile Viruses. *PLoS Neglected Tropical Diseases* 11:e0005275. DOI: 10.1371/journal.pntd.0005275.

L'Huillier AG, Lombos E, Tang E, Perusini S, Eshaghi A, Nagra S, Frantz C, Olsha R, Kristjanson E, Dimitrova K, Safronetz D, Drebot M, Gubbay JB. 2017. Evaluation of altona diagnostics RealStar zika virus reverse transcription-PCR test kit for Zika virus PCR testing. *Journal of Clinical Microbiology* 55:1576– 1584. DOI: 10.1128/JCM.02153-16.

Long, K.C., Ziegler, S.A., Thangamani, S., et al., 2011. Experimental transmission of Mayaro virus by Aedes aegypti. Am. J. Trop. Med. Hyg. 85, 750–757.

Lura T, Su T, Brown MQ. 2019. Preliminary evaluation of Thermo Fisher TaqMan® Triplex q-PCR kit for simultaneous detection of chikungunya, dengue, and Zika viruses in mosquitoes. *Journal of Vector Ecology* 44:205–209. DOI: 10.1111/jvec.12347.

Mat Jusoh TNA, Shueb RH. 2017. Performance Evaluation of Commercial Dengue Diagnostic Tests for Early Detection of Dengue in Clinical Samples. *Journal of Tropical Medicine* 2017. DOI: 10.1155/2017/4687182.

Medlock JM, Hansford KM, Vaux AGC, Cull B, Gillingham E, Leach S. 2019. Assessment of the Public Health Threats Posed by Vector-Borne Disease in the United Kingdom (UK). Int J Environ Res Public Health. 2018 Sep 29;15(10). pii: E2145. doi: 10.3390/ijerph15102145.

Muturi EJ, Kim CH, Alto BW, Berenbaum MR, Schuler MA. 2011. Larval environmental stress alters *Aedes aegypti* competence for Sindbis virus. *Trop Med Int Health* 16:955–964. DOI: 10.1111/j.1365-3156.2011.02796.x.

Pezzi L, Diallo M, Rosa-Freitas MG, Vega-Rua A, Ng LFP, Boyer S, Drexler JF, Vasilakis N, Lourenco-de-Oliveira R, Weaver SC, Kohl A, de Lamballerie X, Failloux AB, Brasil P, Busch M, Diamond MS, Drebot MA, Gallian P, Jaenisch T, LaBeaud AD, Lecuit M, Neyts J, Reusken CB, Ribeiro GS, Rios M, Rodriguez- Morales AJ, Sall A, Simmons G, Simon F, Siqueira AM. 2020. GloPID-R report on Chikungunya, O'nyong-nyong and Mayaro virus, part 5: Entomological aspects. *Antiviral Research* 174. DOI: 10.1016/j.antiviral.2019.104670.

Public Health England. 2014. The characteristics, symptoms, diagnosis and epidemiology of chikungunya, [HYPERLINK "https://www.gov.uk/guidance/chikungunya"]

Serra, O.P., Cardoso, B.F., Ribeiro, A.L.M., et al., 2016. Mayaro virus and dengue virus 1 and 4 natural infection in culicids from Cuiabá, state of Mato Grosso, Brazil. Mem. Inst. Oswaldo Cruz 111, 20–29.

Souza-Neto JA, Powell JR, Bonizzoni M. 2019. Aedes aegypti vector competence studies: A review. [HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/30465912" \o "Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases."] 2019 Jan;67:191-209. doi: 10.1016/j.meegid.2018.11.009.

Weaver SC, Reisen WK. 2010. Present and future arboviral threats. *Antiviral Research* 85:328–345. DOI: 10.1016/j.antiviral.2009.10.008.

Wiggins, K., Eastmond, B., Alto, B.W., 2018. Transmission potential of Mayaro virus in Florida Aedes aegypti and Aedes albopictus mosquitoes. Med. Vet. Entomol. 32, 436–442.